Focusing on dividend stocks investing and financial independence. Follow the latest news, analysis, rating changes of popular dividend stocks.
April 18, 2016
Piper Jaffray Downgrades Allergan (AGN)
Piper Jaffray downgraded Allergen (NYSE: AGN) from Overweight to Neutral with a price target of $238.00 (from $311.00), saying the valuation premium looks excessive.
Analyst David Amsellem commented, "We are downgrading Allergan to Neutral from Overweight and lowering our PT to $238 from $311. We took a close look at U.S. prescription (Rx) volumes across the commercial portfolio, as well as pricing action over the past two years for over 75 products.
Source: StreetInsider